-
1
-
-
0017159791
-
Eastern Cooperative Oncology Group studies with DTIC (NSC-45388)
-
Carbone P, Costello W: Eastern Cooperative Oncology Group studies with DTIC (NSC-45388). Cancer Treat Rep 60:1287-1295, 1976
-
(1976)
Cancer Treat Rep
, vol.60
, pp. 1287-1295
-
-
Carbone, P.1
Costello, W.2
-
2
-
-
0015465092
-
Phase II evaluation of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU, NSC-409962) in patients with solid tumors
-
Ramirez G, Wilson W, Grage T, et al: Phase II evaluation of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU, NSC-409962) in patients with solid tumors. Cancer Treat Rep 56:787-790, 1972
-
(1972)
Cancer Treat Rep
, vol.56
, pp. 787-790
-
-
Ramirez, G.1
Wilson, W.2
Grage, T.3
-
3
-
-
0026551390
-
Effective combination chemo/hormonal therapy for malignant melanoma: Experience with three consecutive trials
-
McClay EF, Mastrangelo MJ, Berd D, et al: Effective combination chemo/hormonal therapy for malignant melanoma: Experience with three consecutive trials. Int J Cancer 50:553-556, 1992
-
(1992)
Int J Cancer
, vol.50
, pp. 553-556
-
-
McClay, E.F.1
Mastrangelo, M.J.2
Berd, D.3
-
4
-
-
0024504718
-
The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma
-
McClay EF, Mastrangelo MJ, Sprandio JD, et al: The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma. Cancer 63:1292-1295, 1989
-
(1989)
Cancer
, vol.63
, pp. 1292-1295
-
-
McClay, E.F.1
Mastrangelo, M.J.2
Sprandio, J.D.3
-
5
-
-
0029917778
-
The addition of tamoxifen to dacarbazine and cisplatin in metastatic malignant melanoma
-
Flaherty LE, Liu PY, Mitchell MS, et al: The addition of tamoxifen to dacarbazine and cisplatin in metastatic malignant melanoma. Am J Clin Oncol 19:108-113, 1996
-
(1996)
Am J Clin Oncol
, vol.19
, pp. 108-113
-
-
Flaherty, L.E.1
Liu, P.Y.2
Mitchell, M.S.3
-
6
-
-
0004993453
-
Comparison of patient characteristics and outcome between a single institution and cooperative group phase II trial in metastatic melanoma with identical eligibility
-
abstr 1352
-
Flaherty L, Liu PY, Smith D, et al: Comparison of patient characteristics and outcome between a single institution and cooperative group phase II trial in metastatic melanoma with identical eligibility. Proc Am Soc Clin Oncol 13:397, 1994 (abstr 1352)
-
(1994)
Proc Am Soc Clin Oncol
, vol.13
, pp. 397
-
-
Flaherty, L.1
Liu, P.Y.2
Smith, D.3
-
7
-
-
0027050761
-
Modulation of cisplatin resistance in human malignant melanoma cells
-
McClay EF, Albright KD, Jones JA, et al: Modulation of cisplatin resistance in human malignant melanoma cells. Cancer Res 52:6790-6796, 1992
-
(1992)
Cancer Res
, vol.52
, pp. 6790-6796
-
-
McClay, E.F.1
Albright, K.D.2
Jones, J.A.3
-
8
-
-
0027533945
-
Tamoxifen modulation of cisplatin sensitivity in human malignant melanoma cells
-
McClay EF, Albright KD, Jones JA, et al: Tamoxifen modulation of cisplatin sensitivity in human malignant melanoma cells. Cancer Res 53:1571-1576, 1993
-
(1993)
Cancer Res
, vol.53
, pp. 1571-1576
-
-
McClay, E.F.1
Albright, K.D.2
Jones, J.A.3
-
9
-
-
0026625695
-
Treatment of metastatic malignant with dacarbazine plus tamoxifen
-
Cocconi G, Bella M, Calabresi F, et al: Treatment of metastatic malignant with dacarbazine plus tamoxifen. N Engl J Med 327:516-523, 1992
-
(1992)
N Engl J Med
, vol.327
, pp. 516-523
-
-
Cocconi, G.1
Bella, M.2
Calabresi, F.3
-
10
-
-
0025293764
-
Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: A review
-
Wadler S, Schwartz EL: Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: A review. Cancer Res 3473-3486, 1990
-
(1990)
Cancer Res
, pp. 3473-3486
-
-
Wadler, S.1
Schwartz, E.L.2
-
11
-
-
0021702431
-
Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma
-
Del Prete SA, Maurer LH, O'Donnell J, et al: Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma. Cancer Treat Rep 68:1403-1405, 1984
-
(1984)
Cancer Treat Rep
, vol.68
, pp. 1403-1405
-
-
Del Prete, S.A.1
Maurer, L.H.2
O'Donnell, J.3
-
12
-
-
0023217283
-
Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma
-
McClay EF, Mastrangelo MJ, Bellet RE, et al: Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma. Cancer Treat Rep 71:465-469, 1987
-
(1987)
Cancer Treat Rep
, vol.71
, pp. 465-469
-
-
McClay, E.F.1
Mastrangelo, M.J.2
Bellet, R.E.3
-
13
-
-
0029097550
-
Dacarbazine, cisplatin and carmustine, with or without tamoxifen, for metastatic melanoma: 5-year follow-up
-
Lattanzi SC, Tosteson T, Cliertoff J, et al: Dacarbazine, cisplatin and carmustine, with or without tamoxifen, for metastatic melanoma: 5-year follow-up. Melanoma Res 5:365-369, 1995
-
(1995)
Melanoma Res
, vol.5
, pp. 365-369
-
-
Lattanzi, S.C.1
Tosteson, T.2
Cliertoff, J.3
-
14
-
-
0026046196
-
High-dose cisplatin with dacarbazine and tamoxifen in the treatment of metastatic melanoma
-
Buzaid AC, Murren JR, Durivage HJ: High-dose cisplatin with dacarbazine and tamoxifen in the treatment of metastatic melanoma. Cancer 68:1238-1241, 1991
-
(1991)
Cancer
, vol.68
, pp. 1238-1241
-
-
Buzaid, A.C.1
Murren, J.R.2
Durivage, H.J.3
-
15
-
-
0344566351
-
High dose tamoxifen does not enhance the activity of dacarbazine in metastatic melanoma: QMP9105
-
abstr 1339
-
Thomson DB, Walpole ET, Beadle GF, et al: High dose tamoxifen does not enhance the activity of dacarbazine in metastatic melanoma: QMP9105. Proc Am Soc Clin Oncol 12:392, 1993 (abstr 1339)
-
(1993)
Proc Am Soc Clin Oncol
, vol.12
, pp. 392
-
-
Thomson, D.B.1
Walpole, E.T.2
Beadle, G.F.3
-
16
-
-
0345049896
-
Tamoxifen does not improve response when added to chemotherapy in metastatic melanoma. An Italian trials in medical oncology
-
abstr 1345
-
Bajetta E, Zampino MG, Noie F, et al: Tamoxifen does not improve response when added to chemotherapy in metastatic melanoma. An Italian trials in medical oncology. Proc Am Soc Clin Oncol 12:393, 1993 (abstr 1345)
-
(1993)
Proc Am Soc Clin Oncol
, vol.12
, pp. 393
-
-
Bajetta, E.1
Zampino, M.G.2
Noie, F.3
-
17
-
-
0344538063
-
Carboplatin (C) and dacarbazine (D) ± tamoxifen (T) for metastatic melanoma
-
abstr 1358
-
Ferri W, Kirkwood JM, Vlock D, et al: Carboplatin (C) and dacarbazine (D) ± tamoxifen (T) for metastatic melanoma. Proc Am Soc Clin Oncol 12:396, 1993 (abstr 1358)
-
(1993)
Proc Am Soc Clin Oncol
, vol.12
, pp. 396
-
-
Ferri, W.1
Kirkwood, J.M.2
Vlock, D.3
-
18
-
-
0001137782
-
Short course, high-dose tamoxifen (TAM) with cytotoxic chemotherapy for metastatic melanoma
-
abstr 1016
-
Berd D, McLaughlin CJ, Hart E, et al: Short course, high-dose tamoxifen (TAM) with cytotoxic chemotherapy for metastatic melanoma. Proc Am Soc Clin Oncol 10:291, 1991 (abstr 1016)
-
(1991)
Proc Am Soc Clin Oncol
, vol.10
, pp. 291
-
-
Berd, D.1
McLaughlin, C.J.2
Hart, E.3
-
19
-
-
0344187668
-
Lack of benefit from tamoxifen (T) added to a regimen of cisplatin (C), vinblastine (V), DTIC (D) and alpha interferon (IFN) in patients (PT) with metastatic melanoma (MM)
-
abstr 1325
-
Legha S, Ring S, Bedikian A, et al: Lack of benefit from tamoxifen (T) added to a regimen of cisplatin (C), vinblastine (V), DTIC (D) and alpha interferon (IFN) in patients (PT) with metastatic melanoma (MM). Proc Am Soc Clin Oncol 12:388, 1993 (abstr 1325)
-
(1993)
Proc Am Soc Clin Oncol
, vol.12
, pp. 388
-
-
Legha, S.1
Ring, S.2
Bedikian, A.3
-
20
-
-
0013569012
-
A randomized phase III trial of dacarbazine (DTIC) versus DTlC + interferon alfa-2b (IFN) versus DTIC + tamoxifen (TMX) versus DTIC + IFN + TMX in metastatic malignant melanoma: An ECOG trial
-
abstr 1350
-
Falkson CI, Ibrahim J, Kirkwood J, et al: A randomized phase III trial of dacarbazine (DTIC) versus DTlC + interferon alfa-2b (IFN) versus DTIC + tamoxifen (TMX) versus DTIC + IFN + TMX in metastatic malignant melanoma: An ECOG trial. Proc Am Soc Clin Oncol 15:435, 1996 (abstr 1350)
-
(1996)
Proc Am Soc Clin Oncol
, vol.15
, pp. 435
-
-
Falkson, C.I.1
Ibrahim, J.2
Kirkwood, J.3
-
21
-
-
8944261598
-
Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma
-
Rusthoven JJ, Quirt IC, Iscoe NA, et al: Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. J Clin Oncol 14:2083-2090, 1996
-
(1996)
J Clin Oncol
, vol.14
, pp. 2083-2090
-
-
Rusthoven, J.J.1
Quirt, I.C.2
Iscoe, N.A.3
-
22
-
-
0027280177
-
Evaluation of cisplatin and DTIC in inoperable stage III and IV melanoma
-
Fletcher WS, Daniels SD, Sondak VK, et al: Evaluation of cisplatin and DTIC in inoperable stage III and IV melanoma. Am J Clin Oncol 16:359-362, 1993
-
(1993)
Am J Clin Oncol
, vol.16
, pp. 359-362
-
-
Fletcher, W.S.1
Daniels, S.D.2
Sondak, V.K.3
-
23
-
-
0000365082
-
Phase III trial of Melacine melanoma theraccine versus combination chemotherapy in the treatment of stage IV melanoma
-
abstr
-
Mitchell MS, Von Eschen KB: Phase III trial of Melacine melanoma theraccine versus combination chemotherapy in the treatment of stage IV melanoma. Proc Am Soc Clin Oncol 16:494, 1997 (abstr)
-
(1997)
Proc Am Soc Clin Oncol
, vol.16
, pp. 494
-
-
Mitchell, M.S.1
Von Eschen, K.B.2
-
24
-
-
0010552593
-
Alpha interferon and chemo-hormonal therapy in advanced melanoma: A phase I-II NBSG/MAOP study
-
abstr 1341
-
Stark JJ, Schulof R, Wiemann M, et al: Alpha interferon and chemo-hormonal therapy in advanced melanoma: A phase I-II NBSG/MAOP study. Proc Am Soc Clin Oncol 12:392, 1993 (abstr 1341)
-
(1993)
Proc Am Soc Clin Oncol
, vol.12
, pp. 392
-
-
Stark, J.J.1
Schulof, R.2
Wiemann, M.3
-
25
-
-
0029040035
-
Phase II trial of recombinant interferon-α with BCNU, cisplatin, DTIC and tamoxifen in advanced malignant melanoma
-
Feun LG, Savaraj N, Moffat F, et al: Phase II trial of recombinant interferon-α with BCNU, cisplatin, DTIC and tamoxifen in advanced malignant melanoma. Melanoma Res 5:273-276, 1995
-
(1995)
Melanoma Res
, vol.5
, pp. 273-276
-
-
Feun, L.G.1
Savaraj, N.2
Moffat, F.3
-
26
-
-
0013613001
-
A phase-II study of biochemotherapy using interleukin-2 (IL-2) + interferon alfa-2a (IFN) in combination with cisplatin (C), vinblastine (V), and DTIC (D) in patients with metastatic melanoma
-
abstr 1179
-
Legha S, Plager C, Ring S, et al: A phase-II study of biochemotherapy using interleukin-2 (IL-2) + interferon alfa-2a (IFN) in combination with cisplatin (C), vinblastine (V), and DTIC (D) in patients with metastatic melanoma. Proc Am Soc Clin Oncol 11:343, 1992 (abstr 1179)
-
(1992)
Proc Am Soc Clin Oncol
, vol.11
, pp. 343
-
-
Legha, S.1
Plager, C.2
Ring, S.3
-
27
-
-
0026734180
-
Sequential chemoimmunotherapy in the treatment of metastatic melanoma
-
Richards JM, Mehta N, Ramming K, et al: Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol 10:1338-1343, 1992
-
(1992)
J Clin Oncol
, vol.10
, pp. 1338-1343
-
-
Richards, J.M.1
Mehta, N.2
Ramming, K.3
-
28
-
-
0027486041
-
Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma
-
Khayat D, Borel C, Tourani JM, et al: Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma. J Clin Oncol 11:2173-2180, 1993
-
(1993)
J Clin Oncol
, vol.11
, pp. 2173-2180
-
-
Khayat, D.1
Borel, C.2
Tourani, J.M.3
-
29
-
-
0004646475
-
BCNU (B), cisplatin (C), dacarbazine (D) and tamoxifen (T) (BCDT) in metastatic melanoma (MM): Results of a randomized phase II study
-
abstr 1782
-
Chiarion Sileni V, Nortilli R, Medici M, et al: BCNU (B), cisplatin (C), dacarbazine (D) and tamoxifen (T) (BCDT) in metastatic melanoma (MM): results of a randomized phase II study. Proc Am Soc Clin Oncol 16:495a, 1997 (abstr 1782)
-
(1997)
Proc Am Soc Clin Oncol
, vol.16
-
-
Chiarion Sileni, V.1
Nortilli, R.2
Medici, M.3
|